CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Net Inc. Y/Y Annual
Lantheus Holdings Inc   (LNTH)
Other Ticker:  
 
 

LNTH's Net Income Growth by Quarter and Year

Lantheus Holdings Inc 's Net Income results by quarter and year




LNTH Net Income (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 103.38 -119.19 -40.22
III Quarter September - 131.96 61.23 -13.42
II Quarter June 62.07 94.13 43.06 -26.66
I Quarter March 131.07 -2.81 42.96 9.01
FY   193.14 326.66 28.06 -71.29



LNTH Net Income second quarter 2024 Y/Y Growth Comment
Lantheus Holdings Inc reported fall in Net Income in the second quarter 2024 by -34.06% to $ 62.07 millions, from the same quarter in 2023.
The drop in the second quarter 2024 Lantheus Holdings Inc 's Net Income compares unfavorably to the Company's average Net Income doubling of 125.84%.

Among companies who have reported second quarter 2024 results in the In Vitro & In Vivo Diagnostic Substances industry only one Company has achieved higher year on year Net Income results in the second quarter 2024. While Lantheus Holdings Inc ' s Net Income drop of -34.06% ranks overall at the positon no. 1389 in the second quarter 2024.


LNTH Net Income ( Y/Y Growth %) 2024
 2023 2022 2021
IV Quarter December - - - -
III Quarter September - 115.52 % - -
II Quarter June -34.06 % 118.6 % - -
I Quarter March - - 376.8 % 169.76 %
FY   - 1064.15 % - -

Financial Statements
Lantheus Holdings Inc 's second quarter 2024 Net Income $ 62.07 millions LNTH's Income Statement
Lantheus Holdings Inc 's second quarter 2023 Net Income $ 94.13 millions Quarterly LNTH's Income Statement
New: More LNTH's historic Net Income Growth >>


LNTH Net Income (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
IV Quarter December - -21.66 % - -
III Quarter September - 40.19 % 42.2 % -
II Quarter June -52.64 % - 0.23 % -
I Quarter March 26.78 % - - -
FY (Year on Year)   - 1064.15 % - -


Compare LNTH Profitability >> Back to LNTH Growth rate Comparisons >>


Net Income second quarter 2024 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #2
Healthcare Sector #85
Overall #1389

Net Income Y/Y Growth Statistics
High Average Low
1894.78 % 125.84 % -86.31 %
(Dec 31 2017)   (Dec 31 2018)
Net Income second quarter 2024 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #2
Healthcare Sector #85
Overall #1389
Net Income Y/Y Growth Statistics
High Average Low
1894.78 % 125.84 % -86.31 %
(Dec 31 2017)   (Dec 31 2018)

Net Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Lantheus Holdings Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
1039.17 % 55.42 % -91.55 %
(Dec 31 2017)  


LNTH's II. Quarter Q/Q Net Income Comment
In the II. Quarter 2024 Lantheus Holdings Inc disclosed fall in Net Income from the first quarter by -52.64% to $ 62.07 millions, from $ 131.07 millions achived a quarter before.

Within In Vitro & In Vivo Diagnostic Substances industry only one company achieved higher sequential Net Income growth. While Lantheus Holdings Inc 's Net Income growth quarter on quarter, overall rank is 1567.


Net Income Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #2
Healthcare Sector #95
Overall #1567
Net Income Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #2
Healthcare Sector #95
Overall #1567
Net Income Q/Q Growth Statistics
High Average Low
1039.17 % 55.42 % -91.55 %
(Dec 31 2017)  


LNTH's II. Quarter Q/Q Net Income Comment
In the II. Quarter 2024 Lantheus Holdings Inc reported fall in Net Income sequentially by -52.64% to $ 62.07 millions, from $ 131.07 millions released in the previous quarter.

Within In Vitro & In Vivo Diagnostic Substances industry only one company achieved higher sequential Net Income growth. While Lantheus Holdings Inc 's Net Income growth quarter on quarter, overall rank is 1567.


Lantheus Holdings Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)
Cumulative Net Income 12 Months Ending $ 428.48 $ 460.53 $ 326.66 $ 104.10 $ 33.37
Y / Y Net Income Growth (TTM) 1183.98 % - 1063.86 % -2.75 % 3.03 %
Year on Year Net Income Growth Overall Ranking # 23 # 23 # 30 # 1069 # 1049
Seqeuential Net Income Change (TTM) -6.96 % 40.98 % 213.81 % 211.94 % -
Seq. Net Income Growth (TTM) Overall Ranking # 23 # # 30 # 1069 # 1049

New: More LNTH's historic Net Income Growth >>



Cumulative Net Income growth Comment
With 1183.98% annual Net Income growth, Lantheus Holdings Inc would report a record annual Net Income surge if the fiscal year would end on Jun 30 2024.

In the Healthcare sector 62 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from to 23.

Net Income TTM Q/Q Growth Statistics
High Average Low
1183.98 %
-271.77 %
-8962.72 %
(Jun 30 2024)  

Net Income TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 2
Healthcare Sector # 63
Overall # 761

Net Income TTM Y/Y Growth Statistics
High Average Low
1183.98 %
-271.77 %
-8962.72 %
(Jun 30 2024)  


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 12
S&P 500 # 98
Cumulative Net Income growth Comment
With 1183.98% annual Net Income growth, Lantheus Holdings Inc would report a record annual Net Income surge if the fiscal year would end on Jun 30 2024.

In the Healthcare sector 62 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from to 23.

Net Income TTM Q/Q Growth Statistics
High Average Low
1183.98 %
-271.77 %
-8962.72 %
(Jun 30 2024)  


Net Income TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 2
Healthcare Sector # 63
Overall # 761

Net Income TTM Y/Y Growth Statistics
High Average Low
1183.98 %
-271.77 %
-8962.72 %
(Jun 30 2024)  


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 12
S&P 500 # 98




Other Net Income Growth
In Vitro & In Vivo Diagnostic Substances Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
LNTH's Net Income Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for LNTH's Competitors
Net Income Growth for Lantheus Holdings Inc 's Suppliers
Net Income Growth for LNTH's Customers

You may also want to know
LNTH's Annual Growth Rates LNTH's Profitability Ratios LNTH's Asset Turnover Ratio LNTH's Dividend Growth
LNTH's Roe LNTH's Valuation Ratios LNTH's Financial Strength Ratios LNTH's Dividend Payout Ratio
LNTH's Roa LNTH's Inventory Turnover Ratio LNTH's Growth Rates LNTH's Dividend Comparisons



Companies with similar Net Income surge for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Net Income for the quarter ending Jun 30 2024
Biogen Inc -1.63%$ -1.635 millions
Embecta Corp -3.29%$ -3.289 millions
Quest Diagnostics Inc-3.61%$ -3.614 millions
Abbott Laboratories-5.31%$ -5.309 millions
Zoetis Inc -6.87%$ -6.866 millions
Idexx Laboratories Inc-9.34%$ -9.337 millions
Prestige Consumer Healthcare Inc -11.89%$ -11.893 millions
Align Technology inc -13.64%$ -13.639 millions
National Research Corporation-15.10%$ -15.097 millions
Dariohealth Corp -17.94%$ -17.938 millions
Bristol myers Squibb Company-18.92%$ -18.922 millions
Organon and Co -19.42%$ -19.421 millions
U S Physical Therapy Inc-21.21%$ -21.206 millions
Pacira Biosciences inc -26.69%$ -26.693 millions
Privia Health Group Inc -27.00%$ -26.997 millions
West Pharmaceutical Services Inc -28.24%$ -28.240 millions
Neurocrine Biosciences Inc -31.94%$ -31.937 millions
Abbvie Inc -32.26%$ -32.264 millions
Lifevantage Corp-33.62%$ -33.622 millions
Lantheus Holdings Inc -34.06%$ -34.057 millions
Viemed Healthcare Inc -36.61%$ -36.609 millions
Vaso Corporation-44.26%$ -44.257 millions
Nature s Sunshine Products inc -44.42%$ -44.415 millions
Royalty Pharma Plc-44.67%$ -44.675 millions
Globus Medical Inc -44.97%$ -44.968 millions
Amgen Inc -45.90%$ -45.903 millions
Surgery Partners Inc -50.78%$ -50.780 millions
Radnet Inc -52.29%$ -52.294 millions
Option Care Health Inc -53.63%$ -53.635 millions
Pro dex Inc -58.30%$ -58.303 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com